免疫疗法治疗复发性复发性多发性硬化症的治疗效果修饰剂 - 一个系统性审查和元分析
Christoph Heesen1, Christian Röver2, Susanna Salem2
1Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center, Hamburg, Germany Department of Neurology, University Medical Center, Hamburg, Germany.
概括
年轻的成年人 (<40岁) 患有多发性硬化症 (MS) 经历较少的复发和较慢的残疾进展与疾病修饰疗法 (DMT). 较低的基线扩展残疾状态量表 (EDSS) 分数也预测了复发率的降低.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 多发性硬化症 (MS) 是一种慢性神经系统疾病.
- 临床隔离综合征和复发性MS形式需要有效的治疗方法.
- 免疫疗法是MS的关键治疗策略之一.
研究的目的:
- 评估免疫疗法在特定的MS患者亚组中的疗效.
- 为了确定影响免疫治疗结果的治疗效果修饰剂 (TEMs).
- 分析对复发率和残疾进展的影响.
主要方法:
- 对2期和3期随机对照试验 (RCT) 与安慰剂对照者的系统分析.
- 包括31项评估各种疾病修饰疗法 (DMT) 的研究.
- 随机效应元分析用于比较子组内和子组之间的治疗效应.
主要成果:
- 40岁以下的年龄是最强的TEM,与复发率的1.44比率比率 (RRR) 和残疾进展的1.59比率危险比率 (RHR) 相关.
- 患有较低基线扩大残疾状态量表 (EDSS) 评分 (≤2.0或≤3.0) 的患者在复发率方面显著获得更大的好处 (RRR 1.35).
- 性别,基线MRI,先前的免疫疗法和临床表现并没有显著改变治疗效果.
结论:
- 年龄<40岁是减少复发率和在多种多发性硬化症免疫疗法中减缓残疾进展的强有力的预测因素.
- 较低的基线EDSS分数在复发率方面预测了更好的反应.
- 这些发现有助于根据患者特征个性化MS治疗策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:27Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484
01:19Antiasthma Drugs: Leukotriene Modifiers
246
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
246
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124